The present disclosure relates generally to the field of stem cells and the hypothermic storage and distribution of those cells. More specifically, the present disclosure provides a method of maintaining the packaged cells at or below 10° C. for extended periods of time during worldwide shipping times and conditions.
Early successes of cell therapy in applications such as the repair of diseased hearts, and treatment of Type 1 diabetes support the notion that the use of cells and tissues to treat disease states is one of the most promising avenues in contemporary medical treatment. In part, many cell therapy applications evolved indirectly from the launch of tissue engineering ventures that led to commercial development of engineered products such as skin and cartilage. Cell and tissue therapy has showcased its potential in medicine through recent clinical trials and is maturing under the new rubric of regenerative/reparative medicine.
The emergence of cell- and tissue-based technologies and the move toward a global marketplace are creating a demand for new technologies that allow worldwide shipment of such products while maintaining their viability or function, a concept referred to as biological packaging.
With the formation of worldwide shipping carriers such as FedEx and UPS, packages of all types can be shipped worldwide and delivered within 3 days. This transcontinental shipping requires hypothermic preservation solutions and packages that maintain viability and function of the cells following sequential storage intervals for transport that approach a week in duration.
The principles governing the development of effective biological packaging necessitate an understanding of state-of-the-art hypothermic storage and cryopreservation, the two standard approaches currently used for preserving cells and tissues for extended periods. Comparing and contrasting these two processes can initiate a dialog to define the challenges that each system must overcome to serve the future needs of the regenerative medicine market and the bioprocessing community at large. Hypothermic storage can be defined as the preservation of cells and tissues at chilled temperatures that often range from about 4° C. to about 10° C.; whereas cryopreservation can be defined as the storage of cells and tissues at subzero temperatures that typically range from about −80° C. to about −196° C.
A comparison is useful for determining which procedure is appropriate for a given therapeutic or bioprocessing application. For instance, if cells are to be shipped short distances or held in “stasis” before use, then hypothermic storage may be employed. That is the case with cellular therapy and in cases such as the on-demand use of cell plates for drug testing and toxicity screening.
Selection of an appropriate preservation regime depends on a number of factors, and time of storage is a key consideration. Other factors, including shipment method, in-house and end-user storage, and end use also can play a role in determining storage methodologies. Regardless of whether hypothermic storage or cryopreservation is the storage regime, formulation of the storage solution and the form factor utilized for containment are also variables to consider.
The present disclosure provides a method of hypothermic storage and shipping for cells, e.g., stem cells and differentiated organ stem cells, for global distribution. In one embodiment, the present disclosure is directed to a method of packaging and the distribution of living cells, in particular iPSc and differentiated iPSc such as cardiomyocytes, neurons, hepatocytes, as well as renal, islet, muscle skeletal, blood, and connective tissue, by means of a disposable hypothermic cooling box that utilizes no ice, or cryogenic materials, such as liquid nitrogen or solid carbon dioxide, and maintains a localized temperature in the storage area of from about 1° C. to about 10° C. In one embodiment, the present disclosure provides a method of transporting a living cell product that is subjected to conditions below ambient temperatures (and above freezing), thereby providing for cooling of the cell product from about 1 hour to about 120 hours. The method includes placing a living cell containing microplate array within the compartment defined by top, side and bottom walls, placing a sorption-cooling device in thermal communication with the compartment where the microplate array with cells is placed, activating the sorption cooling device, sealing the box to prevent accidental opening, and shipping the box from point A to point B anywhere on the globe. The cells in the box when they arrive at point B are viable, e.g., at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or more the viability of corresponding cells before shipping, and, if they are stem cells, capable of differentiation at efficiencies similar to cells before shipping.
In one embodiment, a method of preparing living cells for packaging and distribution is provided. The method includes providing a receptacle having a compartment and a lid, wherein at least a portion of the compartment comprises an insulating material having a predefined thickness and predefined thermal conductivity which can maintain a temperature of about 1° C. to about 10° C. for at least 24 hours in the compartment. The lid may be part of the receptacle or may be independent of the receptacle. Also provided are a sorption device which comprises a passive heat absorbing material and a cell culture substrate having living cells in media. The cell culture substrate and the sorption-cooling device are placed in the compartment. The sorption-cooling device may be activated before or after placement into the compartment. The lid is then disposed over the compartment, and optionally the receptacle having the lid disposed thereon is sealed, to allow for a temperature of about 1° C. to about 10° C. for at least 24 hours in the compartment. In one embodiment, the cells are iPSc. In one embodiment, the cells are differentiated iPSc. In one embodiment, the insulating material can maintain a temperature of about 4° C. to about 10° C. for at least 24 hours. In one embodiment, the temperature is maintained for at least 96 hours. In one embodiment, the substrate is a multiwell plate. In one embodiment, the substrate with a lid so as to provide a water-proof barrier. In one embodiment, the compartment in the receptacle has a temperature of about 4° C. to about 10° C. 24 hours after sealing. In one embodiment, the compartment further comprises a temperature sensor. In one embodiment, the cells have a viability of at least 25% up to at least 90% 24 hours after sealing. In one embodiment,
the cells have a viability of at least 25% up to at least 90% 96 hours after sealing. In one embodiment, at least 25% up to at least 90% of the cells are capable of differentiation 24 to 96 hours after sealing.
The present disclosure provides for storage and shipping of living cells, in particular iPSc and cells differentiated from the iPSc, by the use of a package that does not use any ice, or cryogenic materials such as liquid nitrogen or frozen carbon dioxide, in a very small, easy to ship form for extended periods of time.
Referring to
Referring to
The above discussion is meant to be illustrative of the principles and various embodiments of the present disclosure. Numerous variations and modifications will become apparent to those skilled in the art once the above disclosure is fully appreciated. It is intended that the following claims be interpreted to embrace all such variations and modifications.
This application claims the benefit of the filing date of U.S. application Ser. No. 62/217,206, filed on Sep. 11, 2015, the disclosure of which is incorporated by reference herein.
Number | Date | Country | |
---|---|---|---|
62217206 | Sep 2015 | US |